TRINITY TECHNOLOGIES HALTING DRUG PRODUCTION AND DISTRIBUTION to correct "deficiencies in its manufacturing practice that have been identified by the Food and Drug Administration," the Roseville, Mich.-based generic drugs firm said. In an Aug. 6 statement, Trinity Technologies reported that "approximately half" of its 60 employees have been laid off indefinitely. The private company manufactures approximately 13 generic, primarily prescription drugs, under its own and other labels. About four weeks prior to the announcement of its shutdown, Trinity was notified by FDA that the company was being denied a certificate of free sale. The company said it had requested the certificate for an export order due, but was denied by FDA because of noncompliance with current good manufacturing practices (cGMPs), the company said. Trinity subsequently requested a meeting with FDAers from the agency's Detroit district office. Following the Aug. 5 meeting, Trinity decided to cease production in its 30,000 square-foot plant to correct deficiencies, chiefly related to process validation, the firm said. Trinity has conducted two drug recalls in 1993, one attributed to short fill and one because the expiration date was not supported by stability data. The firm recalled 600 bottles of 1,000 tablets of phenazopyridine on May 28, for short fill that were distributed under the Rugby, Qualitest and Trinity Technologies labels. In December 1992, 1,000 bottles of 100 tablets each of Prop-A-Hist antihistamine-decongestant caplets distributed by Bolan Pharmaceutical were recalled by Trinity because of an incorrect expiration date (see Enforcement Report below.) In the fall of 1991, the firm recalled 1,464 1,000-tablet and 601 100-tablet bottles of colchicine, a gout treatment. The reason cited was failure to meet dissolution specification. All three recalls were categorized as Class III. Trinity Technologies was founded in 1984 by Walter and Matthew Szczesiul. Matthew Szczesiul is president of the firm, which manufactures primarily solid dosage forms. In the first half of 1993, Trinity had sales of about $ 4.7 mil.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.
